Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving ...

Although global inequalities in survival from childhood leukemia have narrowed, they still persist with five-year survival in some countries nearly twice as high as in others for children diagnosed ...

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone ...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. It affects people of all ages but is most common in those over 65. Around 150 people are diagnosed with the disease each year in ...

New research into acute myeloid leukemia could change future treatment approaches.

Hyperactive signaling pathways of some aggressive blood cancer cells can be tamped down by a previously unrecognized protein complex, ensuring the cancer's survival. If one component of the complex is ...

Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical ...

Findings expand Telomir-1’s oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. In this ...

Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.